FMT in Gut aGVHD Treated

NCT03148743 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Observational

Started

2017-05-16

Last updated

2026-06-01

Condition(s) studied

Acute-graft-versus-host Disease

Investigational drug(s) / intervention(s)

Fecal microbiota

Fecal microbiota: fecal microbiota transplantation

Study summary

With the stem cell transplanting increasing, patients which effected with gut GVHD were also increased. To evaluation the safety and efficacy of FMT for gut GVHD,patients with gut GVHD were recruited.

Eligibility

Sex

ALL

Min age

10 Years

Max age

60 Years

Healthy volunteers

Accepted

Inclusion Criteria: * gut GVHD Exclusion Criteria: * Age\>60; or Age\<10

Primary outcome measure(s)

times of stool — 24hours,48hours,72hours, 96hours,fifth day,sixth day, a week
Change from stool times in a week

Trial sites (1)

Facility	City	Region	Status
中国	Suzhou	Jiangsu	Recruiting

More The First Affiliated Hospital of Soochow University trials in China

A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML Recruiting

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Starting soon

A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia Starting soon

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Active, not recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03148743 on ClinicalTrials.gov ↗ ← All trials in China